Japan Tissue Engineering Co

Japan Tissue Engineering Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Japan Tissue Engineering Co (7774.T) as of Nov 20, 2026 is 48.95. In the previous year, Cash Conversion Cycle (CCC) was 114.48 — a change of -57.24% (lower).

Cash Conversion Cycle

48.95

YoY

-57.24%

Last updated:

Cash Conversion Cycle (CCC) of Japan Tissue Engineering Co is 2026 48.95 . Cash Conversion Cycle (CCC) of Japan Tissue Engineering Co was 2025 114.48 . It decreases by -57.24% lower compared to the previous year.

The Japan Tissue Engineering Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
117.61 JPY
Jan 1, 2020
108.55 JPY
Jan 1, 2021
142.87 JPY
Jan 1, 2022
100.20 JPY
Jan 1, 2023
171.06 JPY
Jan 1, 2024
150.17 JPY
Jan 1, 2025
114.48 JPY
Jan 1, 2026
48.95 JPY
The Japan Tissue Engineering Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
48.95-57.24%
114.48-23.77%
150.17-12.21%
171.06+70.71%
100.20-29.86%
142.87+31.62%
108.55-7.71%
117.61+6.75%
110.18-31.98%
161.97+24.67%
129.92-10.64%
145.39+6.73%
136.23—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Japan Tissue Engineering Co Stock analysis

What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Japan Tissue Engineering Co stock

Cash Conversion Cycle (CCC) of Japan Tissue Engineering Co is 48.95 in 2026.

Cash Conversion Cycle (CCC) of Japan Tissue Engineering Co changed from 114.48 to 48.95, representing a -57.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Japan Tissue Engineering Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Japan Tissue Engineering Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Japan Tissue Engineering Co

All Key Metrics — Japan Tissue Engineering Co